Click to Translate to English Click to Translate to French  Click to Translate to Spanish  Click to Translate to German  Click to Translate to Italian  Click to Translate to Japanese  Click to Translate to Chinese Simplified  Click to Translate to Korean  Click to Translate to Arabic  Click to Translate to Russian  Click to Translate to Portuguese  Click to Translate to Myanmar (Burmese)

PANDEMIC ALERT LEVEL
123456
Forum Home Forum Home > Main Forums > General Discussion
  New Posts New Posts RSS Feed - A Common Disease Agent Weaponised
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

Tracking the next pandemic: Avian Flu Talk

A Common Disease Agent Weaponised

 Post Reply Post Reply
Author
Message
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Topic: A Common Disease Agent Weaponised
    Posted: February 08 2007 at 6:21pm

About the Author:

Donald Scott, MA, MSc, is a retired high school teacher and university professor. He is also a veteran of WWII and was awarded the North Atlantic Star, the Burma Star with Clasp, the 1939-1945 Volunteer Service Medal and the Victory Medal.

He is currently President of The Common Cause Medical Research Foundation, a not-for-profit organisation devoted to research into neurosystemic degenerative diseases.
 
He is also Adjunct Professor with the Institute for Molecular Medicine and he produces and edits the Journal of Degenerative Diseases.
 
He has extensively researched neurosystemic degenerative diseases over the past five years and has authored many documents on the relationship between degenerative diseases and a pathogenic mycoplasma called Mycoplasma fermentans. His research is based upon solid government evidence.

rainbow bar

 

MYCOPLASMA

The Linking Pathogen in Neurosystemic Diseases

Several strains of mycoplasma have been "engineered" to become more dangerous. They are now being blamed for AIDS, cancer, CFS, MS, CJD and other neurosystemic diseases.


Extracted from Nexus Magazine, Volume 8, Number 5 (August-September 2001)
PO Box 30, Mapleton Qld 4560 Australia. editor@nexusmagazine.com
Telephone: +61 (0)7 5442 9280; Fax: +61 (0)7 5442 9381
From our web page at: www.nexusmagazine.com

© by Donald W. Scott, MA, MSc © 2001
President
The Common Cause
Medical Research Foundation
190 Mountain Street, Suite 405
Sudbury, Ontario, Canada P3B 4G2
Tel/fax: +1 (705) 670 0180


PATHOGENIC MYCOPLASMA

A Common Disease Agent Weaponised

There are 200 species of Mycoplasma. Most are innocuous and do no harm; only four or five are pathogenic. Mycoplasma fermentans (incognitus strain) probably comes from the nucleus of the Brucella bacterium. This disease agent is not a bacterium and not a virus; it is a mutated form of the Brucella bacterium, combined with a visna virus, from which the mycoplasma is extracted.

The pathogenic Mycoplasma used to be very innocuous, but biological warfare research conducted between 1942 and the present time has resulted in the creation of more deadly and infectious forms of Mycoplasma. Researchers extracted this mycoplasma from the Brucella bacterium and actually reduced the disease to a crystalline form. They "weaponised" it and tested it on an unsuspecting public in North America.

Dr Maurice Hilleman, chief virologist for the pharmaceutical company Merck Sharp & Dohme, stated that this disease agent is now carried by everybody in North America and possibly most people throughout the world.

Despite reporting flaws, there has clearly been an increased incidence of all the neuro/systemic degenerative diseases since World War II and especially since the 1970s with the arrival of previously unheard-of diseases like chronic fatigue syndrome and AIDS.

According to Dr Shyh-Ching Lo, senior researcher at The Armed Forces Institute of Pathology and one of America's top mycoplasma researchers, this disease agent causes many illnesses including AIDS, cancer, chronic fatigue syndrome, Crohn's colitis, Type I diabetes, multiple sclerosis, Parkinson's disease, Wegener's disease and collagen-vascular diseases such as rheumatoid arthritis and Alzheimer's.

Dr Charles Engel, who is with the US National Institutes of Health, Bethesda, Maryland, stated the following at an NIH meeting on February 7, 2000: "I am now of the view that the probable cause of chronic fatigue syndrome and fibromyalgia is the mycoplasma..."

I have all the official documents to prove that mycoplasma is the disease agent in chronic fatigue syndrome/fibromyalgia as well as in AIDS, multiple sclerosis and many other illnesses. Of these, 80% are US or Canadian official government documents, and 20% are articles from peer-reviewed journals such as the Journal of the American Medical Association, New England Journal of Medicine and the Canadian Medical Association Journal. The journal articles and government documents complement each other.

How the Mycoplasma Works

The mycoplasma acts by entering into the individual cells of the body, depending upon your genetic predisposition.

You may develop neurological diseases if the pathogen destroys certain cells in your brain, or you may develop Crohn's colitis if the pathogen invades and destroys cells in the lower bowel.

Once the mycoplasma gets into the cell, it can lie there doing nothing sometimes for 10, 20 or 30 years, but if a trauma occurs like an accident or a vaccination that doesn't take, the mycoplasma can become triggered.

Because it is only the DNA particle of the bacterium, it doesn't have any organelles to process its own nutrients, so it grows by uptaking pre-formed sterols from its host cell and it literally kills the cell; the cell ruptures and what is left gets dumped into the bloodstream.

II - CREATION OF THE MYCOPLASMA

A Laboratory-Made Disease Agent

Many doctors don't know about this mycoplasma disease agent because it was developed by the US military in biological warfare experimentation and it was not made public. This pathogen was patented by the United States military and Dr Shyh-Ching Lo. I have a copy of the documented patent from the US Patent Office.1

All the countries at war were experimenting with biological weapons. In 1942, the governments of the United States, Canada and Britain entered into a secret agreement to create two types of biological weapons (one that would kill, and one that was disabling) for use in the war against Germany and Japan, who were also developing biological weapons. While they researched a number of disease pathogens, they primarily focused on the Brucella bacterium and began to weaponise it.

From its inception, the biowarfare program was characterised by continuing in-depth review and participation by the most eminent scientists, medical consultants, industrial experts and government officials, and it was classified Top Secret.

The US Public Health Service also closely followed the progress of biological warfare research and development from the very start of the program, and the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) in the United States were working with the military in weaponising these diseases. These are diseases that have existed for thousands of years, but they have been weaponised--which means they've been made more contagious and more effective. And they are spreading.

The Special Virus Cancer Program, created by the CIA and NIH to develop a deadly pathogen for which humanity had no natural immunity (AIDS), was disguised as a war on cancer but was actually part of MKNAOMI.2 Many members of the Senate and House of Representatives do not know what has been going on. For example, the US Senate Committee on Government Reform had searched the archives in Washington and other places for the document titled "The Special Virus Cancer Program: Progress Report No. 8", and couldn't find it. Somehow they heard I had it, called me and asked me to mail it to them. Imagine: a retired schoolteacher being called by the United States Senate and asked for one of their secret documents! The US Senate, through the Government Reform Committee, is trying to stop this type of government research.

Crystalline Brucella

The title page of a genuine US Senate Study, declassified on February 24, 1977, shows that George Merck, of the pharmaceutical company, Merck Sharp & Dohme (which now makes cures for diseases that at one time it created), reported in 1946 to the US Secretary of War that his researchers had managed "for the first time" to "isolate the disease agent in crystalline form".3

They had produced a crystalline bacterial toxin extracted from the Brucella bacterium. The bacterial toxin could be removed in crystalline form and stored, transported and deployed without deteriorating. It could be delivered by other vectors such as insects, aerosol or the food chain (in nature it is delivered within the bacterium). But the factor that is working in the Brucella is the mycoplasma.

Brucella is a disease agent that doesn't kill people; it disables them. But, according to Dr Donald MacArthur of the Pentagon, appearing before a congressional committee in 1969,4 researchers found that if they had mycoplasma at a certain strength--actually, 10 to the 10th power (1010)--it would develop into AIDS, and the person would die from it within a reasonable period of time because it could bypass the natural human defences. If the strength was 108, the person would manifest with chronic fatigue syndrome or fibromyalgia. If it was 107, they would present as wasting; they wouldn't die and they wouldn't be disabled, but they would not be very interested in life; they would waste away.

Most of us have never heard of the disease brucellosis because it largely disappeared when they began pasteurising milk, which was the carrier. One salt shaker of the pure disease agent in a crystalline form could sicken the entire population of Canada. It is absolutely deadly, not so much in terms of killing the body but disabling it.

Because the crystalline disease agent goes into solution in the blood, ordinary blood and tissue tests will not reveal its presence. The mycoplasma will only crystallise at 8.1 pH, and the blood has a pH of 7.4 pH. So the doctor thinks your complaint is "all in your head".

Crystalline Brucella and Multiple Sclerosis

In 1998 in Rochester, New York, I met a former military man, PFC Donald Bentley, who gave me a document and told me: "I was in the US Army, and I was trained in bacteriological warfare. We were handling a bomb filled with brucellosis, only it wasn't brucellosis; it was a Brucella toxin in crystalline form. We were spraying it on the Chinese and North Koreans."

He showed me his certificate listing his training in chemical, biological and radiological warfare. Then he showed me 16 pages of documents given to him by the US military when he was discharged from the service. They linked brucellosis with multiple sclerosis, and stated in one section: "Veterans with multiple sclerosis, a kind of creeping paralysis developing to a degree of 10% or more disability within two years after separation from active service, may be presumed to be service-connected for disability compensation. Compensation is payable to eligible veterans whose disabilities are due to service." In other words: "If you become ill with multiple sclerosis, it is because you were handling this Brucella, and we will give you a pension. Don't go raising any fuss about it." In these documents, the government of the United States revealed evidence of the cause of multiple sclerosis, but they didn't make it known to the public--or to your doctor.

In a 1949 report, Drs Kyger and Haden suggested "the possibility that multiple sclerosis might be a central nervous system manifestation of chronic brucellosis". Testing approximately 113 MS patients, they found that almost 95% also tested positive for Brucella.5 We have a document from a medical journal, which concludes that one out of 500 people who had brucellosis would develop what they call neurobrucellosis; in other words, brucellosis in the brain, where the Brucella settles in the lateral ventricles--where the disease multiple sclerosis is basically located.6

Contamination of Camp Detrick Lab Workers

A 1948 New England Journal of Medicine report titled "Acute Brucellosis Among Laboratory Workers" shows us how actively dangerous this agent is.7 The laboratory workers were from Camp Detrick, Frederick, Maryland, where they were developing biological weapons. Even though these workers had been vaccinated, wore rubberised suits and masks and worked through holes in the compartment, many of them came down with this awful disease because it is so absolutely and terrifyingly infectious.

The article was written by Lt Calderone Howell, Marine Corps, Captain Edward Miller, Marine Corps, Lt Emily Kelly, United States Naval Reserve, and Captain Henry Bookman. They were all military personnel engaged in making the disease agent Brucella into a more effective biological weapon.

III - COVERT TESTING OF MYCOPLASMA

Testing the Dispersal Methods

Documented evidence proves that the biological weapons they were developing were tested on the public in various communities without their knowledge or consent.

The government knew that crystalline Brucella would cause disease in humans. Now they needed to determine how it would spread and the best way to disperse it. They tested dispersal methods for Brucella suis and Brucella melitensis at Dugway Proving Ground, Utah, in June and September 1952. Probably, 100% of us now are infected with Brucella suis and Brucella melitensis.8

Another government document recommended the genesis of open-air vulnerability tests and covert research and development programs to be conducted by the Army and supported by the Central Intelligence Agency.

At that time, the Government of Canada was asked by the US Government to cooperate in testing weaponised Brucella, and Canada cooperated fully with the United States. The US Government wanted to determine whether mosquitoes would carry the disease and also if the air would carry it. A government report stated that "open-air testing of infectious biological agents is considered essential to an ultimate understanding of biological warfare potentialities because of the many unknown factors affecting the degradation of micro-organisms in the atmosphere".9

Testing via Mosquito Vector in Punta Gorda, Florida

A report from The New England Journal of Medicine reveals that one of the first outbreaks of chronic fatigue syndrome was in Punta Gorda, Florida, back in 1957.10 It was a strange coincidence that a week before these people came down with chronic fatigue syndrome, there was a huge influx of mosquitoes.

The National Institutes of Health claimed that the mosquitoes came from a forest fire 30 miles away. The truth is that those mosquitoes were infected in Canada by Dr Guilford B. Reed at Queen's University. They were bred in Belleville, Ontario, and taken down to Punta Gorda and released there.

Within a week, the first five cases ever of chronic fatigue syndrome were reported to the local clinic in Punta Gorda. The cases kept coming until finally 450 people were ill with the disease.

Testing via Mosquito Vector in Ontario

The Government of Canada had established the Dominion Parasite Laboratory in Belleville, Ontario, where it raised 100 million mosquitoes a month. These were shipped to Queen's University and certain other facilities to be infected with this crystalline disease agent. The mosquitoes were then let loose in certain communities in the middle of the night, so that the researchers could determine how many people would become ill with chronic fatigue syndrome or fibromyalgia, which was the first disease to show.

One of the communities they tested it on was the St Lawrence Seaway valley, all the way from Kingston to Cornwall, in 1984. They let out hundreds of millions of infected mosquitoes. Over 700 people in the next four or five weeks developed myalgic encephalomyelitis, or chronic fatigue syndrome.

IV - COVERT TESTING OF OTHER DISEASE AGENTS

Mad Cow Disease/Kuru/CJD in the Fore Tribe

Before and during World War II, at the infamous Camp 731 in Manchuria, the Japanese military contaminated prisoners of war with certain disease agents.

They also established a research camp in New Guinea in 1942. There they experimented upon the Fore Indian tribe and inoculated them with a minced-up version of the brains of diseased sheep containing the visna virus which causes "mad cow disease" or Creutzfeldt-Jakob disease.

About five or six years later, after the Japanese had been driven out, the poor people of the Fore tribe developed what they called kuru, which was their word for "wasting", and they began to shake, lose their appetites and die. The autopsies revealed that their brains had literally turned to mush. They had contracted "mad cow disease" from the Japanese experiments.

When World War II ended, Dr Ishii Shiro--the medical doctor who was commissioned as a General in the Japanese Army so he could take command of Japan's biological warfare development, testing and deployment--was captured. He was given the choice of a job with the United States Army or execution as a war criminal. Not surprisingly, Dr Ishii Shiro chose to work with the US military to demonstrate how the Japanese had created mad cow disease in the Fore Indian tribe.

In 1957, when the disease was beginning to blossom in full among the Fore people, Dr Carleton Gajdusek of the US National Institutes of Health headed to New Guinea to determine how the minced-up brains of the visna-infected sheep affected them. He spent a couple of years there, studying the Fore people, and wrote an extensive report. He won the Nobel Prize for "discovering" kuru disease in the Fore tribe.

Testing Carcinogens over Winnipeg, Manitoba

In 1953, the US Government asked the Canadian Government if it could test a chemical over the city of Winnipeg. It was a big city with 500,000 people, miles from anywhere. The American military sprayed this carcinogenic chemical in a 1,000%-attenuated form, which they said would be so watered down that nobody would get very sick; however, if people came to clinics with a sniffle, a sore throat or ringing in their ears, the researchers would be able to determine what percentage would have developed cancer if the chemical had been used at full strength.

We located evidence that the Americans had indeed tested this carcinogenic chemical--zinc cadmium sulphide--over Winnipeg in 1953. We wrote to the Government of Canada, explaining that we had solid evidence of the spraying and asking that we be informed as to how high up in the government the request for permission to spray had gone. We did not receive a reply.

Shortly after, the Pentagon held a press conference on May 14, 1997, where they admitted what they had done. Robert Russo, writing for the Toronto Star11 from Washington, DC, reported the Pentagon's admission that in 1953 it had obtained permission from the Canadian Government to fly over the city of Winnipeg and spray out this chemical--which sifted down on kids going to school, housewives hanging out their laundry and people going to work. US Army planes and trucks released the chemical 36 times between July and August 1953. The Pentagon got its statistics, which indicated that if the chemical released had been full strength, approximately a third of the population of Winnipeg would have developed cancers over the next five years.

One professor, Dr Hugh Fudenberg, MD, twice nominated for the Nobel Prize, wrote a magazine article stating that the Pentagon came clean on this because two researchers in Sudbury, Ontario--Don Scott and his son, Bill Scott--had been revealing this to the public. However, the legwork was done by other researchers!

The US Army actually conducted a series of simulated germ warfare tests over Winnipeg. The Pentagon lied about the tests to the mayor, saying that they were testing a chemical fog over the city, which would protect Winnipeg in the event of a nuclear attack.

A report commissioned by US Congress, chaired by Dr Rogene Henderson, lists 32 American towns and cities used as test sites as well.

V - BRUCELLA MYCOPLASMA AND DISEASE

AIDS

The AIDS pathogen was created out of a Brucella bacterium mutated with a visna virus; then the toxin was removed as a DNA particle called a mycoplasma. They used the same mycoplasma to develop disabling diseases like MS, Crohn's colitis, Lyme disease, etc.

In the previously mentioned US congressional document of a meeting held on June 9, 1969,12 the Pentagon delivered a report to Congress about biological weapons. The Pentagon stated: "We are continuing to develop disabling weapons." Dr MacArthur, who was in charge of the research, said: "We are developing a new lethal weapon, a synthetic biological agent that does not naturally exist, and for which no natural immunity could have been acquired."

Think about it. If you have a deficiency of acquired immunity, you have an acquired immunity deficiency. Plain as that. AIDS.

In laboratories throughout the United States and in a certain number in Canada including at the University of Alberta, the US Government provided the leadership for the development of AIDS for the purpose of population control. After the scientists had perfected it, the government sent medical teams from the Centers for Disease Control--under the direction of Dr Donald A. Henderson, their investigator into the 1957 chronic fatigue epidemic in Punta Gorda--during 1969 to 1971 to Africa and some countries such as India, Nepal and Pakistan where they thought the population was becoming too large.13 They gave them all a free vaccination against smallpox; but five years after receiving this vaccination, 60% of those inoculated were suffering from AIDS. They tried to blame it on a monkey, which is nonsense.

A professor at the University of Arkansas made the claim that while studying the tissues of a dead chimpanzee she found traces of HIV. The chimpanzee that she had tested was born in the United States 23 years earlier. It had lived its entire life in a US military laboratory where it was used as an experimental animal in the development of these diseases. When it died, its body was shipped to a storage place where it was deep-frozen and stored in case they wanted to analyse it later. Then they decided that they didn't have enough space for it, so they said, "Anybody want this dead chimpanzee?" and this researcher from Arkansas said: "Yes. Send it down to the University of Arkansas. We are happy to get anything that we can get." They shipped it down and she found HIV in it. That virus was acquired by that chimpanzee in the laboratories where it was tested.14

Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis

Chronic fatigue syndrome is more accurately called myalgic encephalomyelitis. The chronic fatigue syndrome nomenclature was given by the US National Institutes of Health because it wanted to downgrade and belittle the disease.

An MRI scan of the brain of a teenage girl with chronic fatigue syndrome displayed a great many scars or punctate lesions in the left frontal lobe area where portions of the brain had literally dissolved and been replaced by scar tissue. This caused cognitive impairment, memory impairment, etc. And what was the cause of the scarring? The mycoplasma. So there is very concrete physical evidence of these tragic diseases, even though doctors continue to say they don't know where it comes from or what they can do about it.

Many people with chronic fatigue syndrome, myalgic encephalo-myelitis and fibromyalgia who apply to the Canada Pensions Plan Review Tribunal will be turned down because they cannot prove that they are ill. During 1999 I conducted several appeals to Canada Pensions and the Workers Compensation Board (WCB, now the Workplace Safety and Insurance Board) on behalf of people who have been turned down. I provided documented evidence of these illnesses, and these people were all granted their pensions on the basis of the evidence that I provided.

In March 1999, for example, I appealed to the WCB on behalf of a lady with fibromyalgia who had been denied her pension back in 1993. The vice-chairman of the board came to Sudbury to hear the appeal, and I showed him a number of documents which proved that this lady was physically ill with fibromyalgia. It was a disease that caused physical damage, and the disease agent was a mycoplasma. The guy listened for three hours, and then he said to me: "Mr Scott, how is it I have never heard of any of this before? I said: "We brought a top authority in this area into Sudbury to speak on this subject and not a single solitary doctor came to that presentation."

VI - TESTING FOR MYCOPLASMA IN YOUR BODY

Polymerase Chain Reaction Test

Information is not generally available about this agent because, first of all, the mycoplasma is such a minutely small disease agent. A hundred years ago, certain medical theoreticians conceived that there must be a form of disease agent smaller than bacteria and viruses. This pathogenic organism, the mycoplasma, is so minute that normal blood and tissue tests will not reveal its presence as the source of the disease.

Your doctor may diagnose you with Alzheimer's disease, and he will say: "Golly, we don't know where Alzheimer's comes from. All we know is that your brain begins to deteriorate, cells rupture, the myelin sheath around the nerves dissolves, and so on." Or if you have chronic fatigue syndrome, the doctor will not be able to find any cause for your illness with ordinary blood and tissue tests.

This mycoplasma couldn't be detected until about 30 years ago when the polymerase chain reaction (PCR) test was developed, in which a sample of your blood is examined and damaged particles are removed and subjected to a polymerase chain reaction. This causes the DNA in the particles to break down. The particles are then placed in a nutrient, which causes the DNA to grow back into its original form. If enough of the substance is produced, the form can be recognised, so it can be determined whether Brucella or another kind of agent is behind that particular mycoplasma.

Blood Test

If you or anybody in your family has myalgic encephalomyelitis, fibromyalgia, multiple sclerosis or Alzheimer's, you can send a blood sample to Dr Les Simpson in New Zealand for testing.

If you are ill with these diseases, your red blood cells will not be normal doughnut-shaped blood cells capable of being compressed and squeezed through the capillaries, but will swell up like cherry-filled doughnuts which cannot be compressed. The blood cells become enlarged and distended because the only way the mycoplasma can exist is by uptaking pre-formed sterols from the host cell. One of the best sources of pre-formed sterols is cholesterol, and cholesterol is what gives your blood cells flexibility. If the cholesterol is taken out by the mycoplasma, the red blood cell swells up and doesn't go through, and the person begins to feel all the aches and pains and all the damage it causes to the brain, the heart, the stomach, the feet and the whole body because blood and oxygen are cut off.

And that is why people with fibromyalgia and chronic fatigue syndrome have such a terrible time. When the blood is cut off from the brain, punctate lesions appear because those parts of the brain die. The mycoplasma will get into portions of the heart muscle, especially the left ventricle, and those cells will die. Certain people have cells in the lateral ventricles of the brain that have a genetic predisposition to admit the mycoplasma, and this causes the lateral ventricles to deteriorate and die. This leads to multiple sclerosis, which will progress until these people are totally disabled; frequently, they die prematurely. The mycoplasma will get into the lower bowel, parts of which will die, thus causing colitis. All of these diseases are caused by the degenerating properties of the mycoplasma.

In early 2000, a gentleman in Sudbury phoned me and told me he had fibromyalgia. He applied for a pension and was turned down because his doctor said it was all in his head and there was no external evidence. I gave him the proper form and a vial, and he sent his blood to Dr Simpson to be tested. He did this with his family doctor's approval, and the results from Dr Simpson showed that only 4% of his red blood cells were functioning normally and carrying the appropriate amount of oxygen to his poor body, whereas 83% were distended, enlarged and hardened, and wouldn't go through the capillaries without an awful lot of pressure and trouble. This is the physical evidence of the damage that is done.

ECG Test

You can also ask your doctor to give you a 24-hour Holter ECG. You know, of course, that an electrocardiogram is a measure of your heartbeat and shows what is going on in the right ventricle, the left ventricle and so on. Tests show that 100% of patients with chronic fatigue syndrome and fibromyalgia have an irregular heartbeat. At various periods during the 24 hours, the heart, instead of working happily away going "bump-BUMP, bump-BUMP", every now and again goes "buhbuhbuhbuhbuhbuhbuhbuhbuh". The T-wave (the waves are called P, Q, R, S and T) is normally a peak, and then the wave levels off and starts with the P-wave again. In chronic fatigue and fibromyalgia patients, the T-wave flattens off, or actually inverts. That means the blood in the left ventricle is not being squeezed up through the aorta and around through the body.

My client from Sudbury had this test done and, lo and behold, the results stated: "The shape of T and S-T suggests left ventricle strain pattern, although voltage and so on is normal." The doctor had no clue as to why the T-wave was not working properly. I analysed the report of this patient who had been turned down by Canada Pensions and sent it back to them. They wrote back, saying: "It looks like we may have made a mistake. We are going to give you a hearing and you can explain this to us in more detail."

So it is not all in your imagination. There is actual physical damage to the heart. The left ventricle muscles do show scarring. That is why many people are diagnosed with a heart condition when they first develop fibromyalgia, but it's only one of several problems because the mycoplasma can do all kinds of damage.

Blood Volume Test

You can also ask your doctor for a blood volume test. Every human being requires a certain amount of blood per pound of body weight, and it has been observed that people with fibromyalgia, chronic fatigue syndrome, multiple sclerosis and other illnesses do not have the normal blood volume their body needs to function properly. Doctors aren't normally aware of this.

This test measures the amount of blood in the human body by taking out 5 cc, putting a tracer in it and then putting it back into the body. One hour later, take out 5 cc again and look for the tracer. The thicker the blood and the lower the blood volume, the more tracer you will find.

The analysis of one of my clients stated: "This patient was referred for red cell mass study. The red cell volume is 16.9 ml per kg of body weight. The normal range is 25 to 35 ml per kg. This guy has 36% less blood in his body than the body needs to function." And the doctor hadn't even known the test existed.

If you lost 36% of your blood in an accident, do you think your doctor would tell you that you are alright and should just take up line dancing and get over it? They would rush you to the nearest hospital and start transfusing you with blood. These tragic people with these awful diseases are functioning with anywhere from 7% to 50% less blood than their body needs to function.

VII - UNDOING THE DAMAGE

The body undoes the damage itself. The scarring in the brain of people with chronic fatigue and fibromyalgia will be repaired. There is cellular repair going on all the time. But the mycoplasma has moved on to the next cell.

In the early stages of a disease, doxycycline may reverse that disease process. It is one of the tetracycline antibiotics, but it is not bactericidal; it is bacteriostatic--it stops the growth of the mycoplasma. And if the mycoplasma growth can be stopped for long enough, then the immune system takes over.

Doxycycline treatment is discussed in a paper by mycoplasma expert Professor Garth Nicholson, PhD, of the Institute for Molecular Medicine.15 Dr Nicholson is involved in a US$8-million mycoplasma research program funded by the US military and headed by Dr Charles Engel of the NIH. The program is studying Gulf War veterans, 450 of them, because there is evidence to suggest that Gulf War syndrome is another illness (or set of illnesses) caused by mycoplasma.


Endnotes:

1. "Pathogenic Mycoplasma", US Patent No. 5,242,820, issued September 7, 1993. Dr Lo is listed as the "Inventor" and the American Registry of Pathology, Washington, DC, is listed as the "Assignee".
2. "Special Virus Cancer Program: Progress Report No. 8", prepared by the National Cancer Institute, Viral Oncology, Etiology Area, July 1971, submitted to NIH Annual Report in May 1971 and updated July 1971.
3. US Senate, Ninety-fifth Congress, Hearings before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, Biological Testing Involving Human Subjects by the Department of Defense, 1977; released as US Army Activities in the US Biological Warfare Programs, Volumes One and Two, 24 February 1977.
4. Dr Donald MacArthur, Pentagon, Department of Defense Appropriations for 1970, Hearings before Subcommittee of the Committee on Appropriations, House of Representatives, Ninety-First Congress, First Session, Monday June 9, 1969, pp 105-144, esp. pp. 114, 129.
5. Kyger, E. R. and Russell L. Haden, "Brucellosis and Multiple Sclerosis", The American Journal of Medical Sciences 1949:689-693.
6. Colmonero et al., "Complications Associated with Brucella melitensis Infection: A Study of 530 Cases", Medicine 1996;75(4).
7. Howell, Miller, Kelly and Bookman, "Acute Brucellosis Among Laboratory Workers", New England Journal of Medicine 1948;236:741.
8. "Special Virus Cancer Program: Progress Report No. 8", ibid., table 4, p. 135.
9. US Senate, Hearings before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, March 8 and May 23, 1977, ibid.
10. New England Journal of Medicine, August 22, 1957, p. 362.
11. Toronto Star, May 15, 1997.
12. Dr Donald MacArthur, Pentagon, Department of Defense Appropriations for 1970, Hearings, Monday June 9, 1969, ibid., p. 129.
13. Henderson, Donald A., "Smallpox: Epitaph for a Killer", National Geographic, December 1978, p. 804.
14. Blum, Deborah, The Monkey Wars, Oxford University Press, New York, 1994.
15. Nicholson, G. L., "Doxycycline treatment and Desert Storm", JAMA 1995;273:618-619.

Recommended Reading:
  • Horowitz, Leonard, Emerging Viruses: Aids and Ebola, Tetrahedron Publishing, USA, 1996.
  • Johnson, Hillary, Osler's Web, Crown Publishers, New York, 1996.
  • Scott, Donald W. and William L. C. Scott, The Brucellosis Triangle, The Chelmsford Publishers (Box 133, Stat. B., Sudbury, Ontario P3E 4N5), Canada, 1998 (US$21.95 + $3 s&h in US).
  • Scott, Donald W. and William L. C. Scott, The Extremely Unfortunate Skull Valley Incident, The Chelmsford Publishers, Canada, 1996 (revised, extended edition available from mid-September 2001; US$16.00 pre-pub. price + US$3 s&h in US).
  • The Journal of Degenerative Diseases (Donald W. Scott, Editor), The Common Cause Medical Research Foundation (Box 133, Stat B., Sudbury, Ontario, P3E 4N5), Canada (quarterly journal; annual subscription: US$25.00 in USA, $30 foreign).
Additional Contacts:
  • Ms Jennie Burke, Australian Biologics, Level 6, 383 Pitt Street, Sydney NSW 2000, Australia tel +61 (0)2 9283 0807, fax +61 (0)2 9283 0910. Australian Biologics does tests for mycoplasma.
  • Consumer Health Organization of Canada, 1220 Sheppard Avenue East #412, Toronto, Ontario, Canada M2K 2S5, tel +1 (416) 490 0986, website www.consumerhealth.org/.
  • Professor Garth Nicholson, PhD, Institute for Molecular Medicine, 15162 Triton Lane, Huntington Beach, CA, 92649-1401, USA, tel +1 (714) 903 2900.
  • Dr Les Simpson, Red Blood Cell Research Ltd, 31 Bath Street, Dunedin, 9001, New Zealand, tel +64 (0)3 471 8540, email rbc.research.limited@xtra.co.nz. (Note: Dr Simpson directs his study to red cell shape analysis, not the mycoplasma hypothesis.)
  • The Mycoplasma Registry for Gulf War Illness, S. & L. Dudley, 303 47th St, J-10 San Diego, CA 92102-5961, tel/fax +1 (619) 266 1116, fax (619) 266 1116, email mycoreg@juno.com.
 
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 08 2007 at 6:39pm

I never expected top see this...

I just tossed up.... deadly mysoplasma...  I do that a lot...put up any combination of words on search... I never thought I'd get an article like this.
 
I also put up things like...Russia perpares for pandemic...etc to see whats brewing.
.
Remember the high up career military... General?   His son and grandson were effected by chems from the viet nam war.  He was pretty shocked by the way the Gov treated the whole thing...his family was living it.
and the poor man had been a cog in it all.
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 08 2007 at 6:43pm
I read this a while ago. Not sure if it conspiracy theory or not but it actually sounded plausible.
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 08 2007 at 6:50pm
 
The genus Mycoplasma is one of several genera within the class Mollicutes. Mollicutes are bacteria which have small genomes, lack a cell wall and have low GC-content (18-40 mol%).
 
There are over 100 recognized species of the genus Mycoplasma. Their genome size ranges from 0.6 - 1.35 megabase-pairs.
 
Mollicutes are parasites or commensals of humans, other animals including insects, and plants;
 
 
 
It's true... that it is highly pathogenic...
 
 
 
.................................................................
 
The pathogenic Mycoplasma used to be very innocuous, but biological warfare research conducted between 1942 and the present time has resulted in the creation of more deadly and infectious forms of Mycoplasma. Researchers extracted this mycoplasma from the Brucella bacterium and actually reduced the disease to a crystalline form. They "weaponised" it and tested it on an unsuspecting public in North America.
............................................................
 
Stupider... things have been done.
 
 
yes... I think you have the right word :) .... unless we see documentation....but would we ever? 
 
I just found this...
 
 
is that Australia?
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 08 2007 at 9:14pm
< =http://mesh.kib.ki.se/swemesh/redirect.cfm>
Mycoplasmatales Infections    < =submit value="More s" name=page> < =submit value=MeSH name=page>
< =http://mesh.kib.ki.se/swemesh/redirect.cfm>< = value=C01.252.400.610.610 name=Mesh_No>
              Mycoplasma Infections    < =submit value="More s" name=page> < =submit value=MeSH name=page>
              About Mycoplasma Infections [Fact Sheet] - New York State Dept. of Health (US)
              Brief fact sheet about Mycoplasma Infection - EDCP
              About the Mycoplasmas [S Razin; ed. S Baron] - Medical Microbiology
              Mycoplasma - Immunosciences Lab, Inc.
              Re: Mycoplasma Infections - Maternal-Child Health Forum
              Pneumonia, Mycoplasma [S Cantu, Jr] - eMedicine
              The M. pneumoniae Genome Project at Univ of Heidelberg (DE)
              Brief information about Ureaplasma Urealyticum (genital) infection - Beach C. for Infertility, Endocrinology and IVF (US), and about the Ureaplasma urealyticum Genome - Univ of Alabama, Birmingham (US)
              About Mycoplasma and Ureaplasma [G Mayer] - Univ of South Carolina (US)
              Ureaplasma Infection [KB Waites] - eMedicine
              Mycoplasmas: Sophisticated, Reemerging, and Burdened by Their Notoriety [Baseman and Tully] - CDC/EID, 1997
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 08 2007 at 9:21pm
 
It's Nasty stuff....
 
 

The Latest Controversies: Food for Thought or the Twilight Zone

On the basis of the above information, the virulence strategies displayed by mycoplasmas are likely the summation of a multitude of biological activities (1).

 
Since no obvious single or group of mycoplasmal properties inextricably correlates with disease manifestations,
 
the proof that mycoplasmas are card-carrying pathogens necessitates thorough and highly specific microbiological, epidemiologic, and diagnostic criteria;
 
detailed descriptions of biochemical, genetic, and immunologic characteristics that distinguish virulent and avirulent mycoplasmas; and reproducibility of the symptoms of disease in experimental animal models or in the natural spread of infection among susceptible populations.
 
The portfolio of available evidence concerning mycoplasma-mediated disease pathogenesis is limited. These scientific shortcomings precipitate misconceptions concerning mycoplasmas as singular agents of infectious diseases, as putative cofactors in the progression of other diseases, and as universal contaminants of cell cultures. Clearly, multiple pathways of interaction with target cells appears to be the modus operandi of the Mycoplasma species. With this conceptual scientific framework as a background, five recently proposed and controversial associations of mycoplasmas to human diseases are worth noting.

AIDS

The role of mycoplasmas in accelerating the progression of AIDS could not have begun under more baffling and circuitous conditions.

 
A virus-like agent that arose through transfection of NIH 3T3 cells with DNA from Kaposi sarcoma tissues of AIDS patients was later shown to be M. fermentans. The spotted history of M. fermentans in rheumatoid arthritis and leukemia and its frequent contamination of cell cultures, along with its contemporary link to AIDS, have been considerable impediments to overcome in its elevation to pathogenic status. However, careful and convincing independent studies by several laboratories have implicated M. fermentans as a cause of systemic infections and organ failure in AIDS patients (4,74). The isolation of M. fermentans from blood and urine samples of HIV-infected persons, its detection by PCR and immunohistochemistry in multiple tissue sites at various stages of AIDS, and its ability to stimulate CD4+ lymphocytes and other immunomodulatory activities implicate this Mycoplasma species as a cofactor in AIDS. Consistent with this possibility, M. fermentans has been shown to act synergistically with HIV to enhance cytopathic effects on human CD4+ lymphocytes. Coincident with these studies, a new Mycoplasma species, Mycoplasma penetrans, also has emerged as a potential cofactor in AIDS progression (75,76). Its isolation almost exclusively from the urine of HIV-infected patients, the extraordinarily high prevalence of antibodies against this mycoplasma in HIV-infected patients and not in HIV-seronegative persons, and its capacity to invade target cells and activate the immune system of HIV-infected patients at various stages of disease correlate with a synergistic role with HIV. Other mycoplasmas, including M. genitalium and Mycoplasma pirum, have also been isolated from AIDS patients and implicated as potential cofactors. However, the proposed role of mycoplasmas as infectious agents and cofactors in AIDS-related disorders still remains a hypothesis without definitive proof. If cofactors of HIV are essential to the development of late stages of HIV-mediated disease, mycoplasmas possess all the prerequisite properties of the consummate helper. Their ability to establish covert or overt chronic and persistent infections with concomitant activation of the immune system, stimulation of cytokine production, and induction of oxidative stress correlate with increased HIV replication and disease progression. Are mycoplasmas irrelevant to AIDS, or are the clinical and microbiological correlations sufficient to imply intimate relationships between HIV and mycoplasmas, especially as the infected host undergoes immunologic distress?

Malignant Transformation

As early as the mid-1960s, mycoplasma-infected cell lines were associated with chromosomal aberrations, altered morphologies, and cell transformation (77,78).

 
These abnormal oncogenic cell traits continued even after the apparent elimination of mycoplasmas, and evidence implied increased tumorigenicity of these transformed cells in animals. This issue has been revisited in studies demonstrating that longterm, persistent mycoplasmal infection of mouse embryo cells initiated a multistage cellular process that resulted in irreversible cell transformation, karyotypic alterations, and tumorigenicity in nude mice (6). Do these oncogenic events associated with mycoplasma-mammalian cell coincubation relate to the ontogeny of human cancers?

Gulf War Syndrome

One of the most controversial current medical issues is whether the multiple acute and chronic symptoms found in veterans of the Persian Gulf War were caused by chemical exposure, infectious agents, or psychological problems, or whether a Gulf War Syndrome exists at all. The clinical illness comprises a collection of symptoms, including chronic fatigue, joint pain, headaches, and skin rashes. One study suggests that pathogenic mycoplasmas are responsible for a large number of cases among veterans,

 
on the basis of DNA hybridization and the responsiveness of veterans to prolonged antibiotic treatment (5). Even though the experimental evidence is sparse and incomplete and well-controlled and detailed studies by independent laboratories are needed, if the Gulf War Syndrome has infectious causes, mycoplasmas with their requisite biological credentials are potential candidates.

Crohn's Disease

Several epidemiologic studies correlate respiratory infections with exacerbation of Crohn's disease and other chronic inflammatory bowel diseases (7,79). Acute onset gastrointestinal symptoms in patients with these diseases are accompanied by seroconversion to specific viral or M. pneumoniae antigens. As indicated earlier, mycoplasmas can elicit pleiotropic immune responses and are difficult to eliminate in patients despite appropriate antibiotic treatment. Steroid therapy to control gastrointestinal symptoms in these patients, along with the multifaceted biological properties associated with pathogenic mycoplasmas, may precipitate the onset of acute exacerbations of chronic inflammatory bowel disease.

Rheumatoid Arthritis and Other Human Arthritides

The occurrence of various Mycoplasma and Ureaplasma species in joint tissues of patients with rheumatoid arthritis, sexually transmitted reactive arthritis, and other human arthritides can no longer be ignored (8).

 
A clinical trial of longterm (6 to 12 months) antibiotic (doxycycline) therapy before cartilage destruction might prove beneficial in managing such frequent and often debilitating infections.

Extensive clinical and microbiological evidence indicates that mycoplasmas alone can elicit a spectrum of illness for which no other agents are incriminated. The eradication of these pathogenic mycoplasmas from various tissue sites requires an intact and functional immune system, although persons with fully competent immune systems may have difficulty eliminating mycoplasmas,

 
even with recommended prolonged drug therapy. Nonetheless, mycoplasmas are still viewed as subordinates to other infectious agents and are relegated to a category of commensals that unwittingly cause disease in patients whose immune systems offer little resistance to microbial stress and overload.

The fundamental importance of mycoplasmas in specific diseases of humans, animals, insects, and plants is irrefutable, and their unique biological properties are consistent with their intimate association with host target cells. These remarkable bacteria must continue to receive the scientific attention of mycoplasmologists, cell culturists, clinicians, immunologists, and DNA sequencers who most recently are compiling extensive databases that may eventually dissect every approachable mycoplasmal element that defines their biological and genetic being. Nonetheless, mycoplasmas remain mysterious and enigmatic, and the available data and proposed hypotheses that correlate mycoplasmas with disease pathogenesis range from definitive, provocative, and titillating to inconclusive, confusing, and heretical. Controversy seems to be a recurrent companion of mycoplasmas, yet good science and openmindedness should overcome the legacy that has burdened them for decades.

Acknowledgments
This study was supported in part by NIH grants AI 27873, AI 32829 and AI 41010.

Dr. Baseman is professor and chair, Department of Microbiology, University of Texas Health Science Center, San Antonio. His research focuses on pathogen-host cell interactions with special interest in defining the biology and virulence determinants of mycoplasmas pathogenic for humans.

Dr. Tully heads the Mycoplasma Section, Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, Frederick, Maryland. His interest covers the host distribution, pathogenicity, and taxonomy of mollicutes.

Address for correspondence: Joel B. Baseman, Department of Microbiology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284-7758; fax: 210-567-6491; e-mail: baseman@uthscsa.edu.

References

  1. Tryon VV, Baseman JB. Pathogenic determinants and mechanisms. In: Maniloff J, McElhaney RN, Finch LR, Baseman JB, editors. Mycoplasmas: molecular biology and pathogenesis. Washington (DC): American Society for Microbiology, 1992:457-71.
  2. Krause DC, Taylor-Robinson D. Mycoplasmas which infect humans. In: Maniloff J, McElhaney RN, Finch LR, Baseman JB, editors. Mycoplasmas: molecular biology and pathogenesis. Washington (DC): American Society for Microbiology, 1992:417-44.
  3. Tully JG. Current status of the mollicute flora of humans. Clin Infect Dis 1993;17:S2-9.
  4. Lo S-C. Mycoplasmas and AIDS. In: Maniloff J, McElhaney RN, Finch LR, Baseman JB, editors. Mycoplasmas: molecular biology and pathogenesis. Washington (DC): American Society for Microbiology, 1992:525-45.
  5. Nicolson G, Nicolson NL. Diagnosis and treatment of mycoplasmal infections in Gulf War illness-CFIDS patients. Intl J Occup Med Immunol Toxicol 1996;5:69-78.
  6. Tsai S, Wear DJ, Shih JW-K, Lo SC. Mycoplasmas and oncogenesis:persistent infection and multistage malignant transformation. Proc Natl Acad Sci USA 1995;92:10197-201.
  7. Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn's disease after in-utero measles virus exposure. Lancet 1996;348:516-7.
  8. Taylor-Robinson D. Mycoplasmas in rheumatoid arthritis and other human arthritides. J Clin Pathol 1996;49:781-2.
  9. Bové JM. Molecular features of mollicutes. Clin Infect Dis 1993;17:S10-31.
  10. Razin S. Molecular properties of mollicutes: a synopsis. In: Razin S, Tully JG, editors. Molecular and diagnostic procedures in mycoplasmology, Vol I. New York: Academic Press, Inc., 1995:1-25.
  11. Dybvig K, Voelker LL. Molecular biology of mycoplasmas. Annu Rev Microbiol 1996;50:25-57.
  12. McGarrity GJ, Kotani H, Butler GH. Mycoplasmas and tissue culture cells. In: Maniloff J, McElhaney RN, Finch LR, Baseman JB, editors. Mycoplasmas: molecular biology and pathogenesis. Washington (DC): American Society for Microbiology, 1992:445-54.
  13. Jacobs E. Mycoplasma pneumoniae virulence factors and the immune response. Rev Med Microbiol 1991;2:83-90.
  14. Baseman JB, Reddy SP, Dallo SF. Interplay between mycoplasma surface proteins, airway cells, and the protean manifestations of mycoplasma-mediated human infections. Am J Respir Crit Care Med 1996;154:S137-44.
  15. Murray HW, Masur H, Senterfit LB, Roberts RB. The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med 1975;58:229-42.
  16. Deguchi T, Gilroy CB, Taylor-Robinson D. Failure to detect Mycoplasma fermentans, Mycoplasma penetrans, or Mycoplasma pirum in the urethra of patients with acute nongonococcal urethritis. Eur J Clin Microbiol Infect Dis 1996;15:169-71.
  17. Williams MH, Brostoff J, Roitt IM. Possible role of Mycoplasma fermentans in pathogenesis of rheumatoid arthritis. Lancet 1970;ii:270-80.
  18. Murphy WH, Gullis C, Dabich L, Heyn R, Zarafonetis CJD. Isolation of Mycoplasma from leukemic and nonleukemia patients. J Nat Cancer Inst 1970;45:243-51.
  19. Schaeverbeke T, Gilroy CB, Bébéar C, Dehais J, Taylor-Robinson D. Mycoplasma fermentans, but not M. penetrans, detected by PCR assays in synovium from patients with rheumatoid arthritis and other rheumatic disorders. J Clin Pathol 1996;41:311-4.
  20. Katseni VL, Gilroy CB, Ryait BK, Ariyoshi K, Bieniasz PB, Weber JN, et al. Mycoplasma fermentans in individuals seropositive and seronegative for HIV-1. Lancet 1993;341:271-3.
  21. Chingbingyong MI, Hughes CV. Detection of Mycoplasma fermentans in human saliva with a polymerase chain reaction-based assay. Archs Oral Biol 1996;41:311-4.
  22. Lo SC, Dawson MS, Newton III PB, Sonoda MA, Shih JW, Engler WF, et al. Association of the virus-like infectious agent originally reported in patients with AIDS with acute fatal disease in previously healthy non-AIDS patients. Amer J Trop Med Hyg 1989;41:364-76.
  23. Tully JG, Taylor-Robinson D, Cole RM, Rose DL. A newly discovered mycoplasma in the human urogenital tract. Lancet 1981;i:1288-91.
  24. Tully JG, Taylor-Robinson D, Rose DL, Furr PM, Graham CE, Barile MF. Urogenital challenge of primate species with Mycoplasma genitalium and characteristics of infection induced in chimpanzees. J Infect Dis 1986;153:1046-54.
  25. Dallo SF, Chavoya A, Su CJ, Baseman JB. DNA and protein sequence homologies detected between the adhesins of Mycoplasma genitalium and Mycoplasma pneumoniae. Infect Immun 1989;57:1059-65.
  26. Palmer HM, Gilroy CB, Thomas BJ, Naidoo ROM, Taylor-Robinson D. Development and evaluation of the polymerase chain reaction to detect Mycoplasma genitalium. FEMS Microbiol Lett 1991;77:199-204.
  27. Horner PJ, Gilroy CB, Thomas BJ, Naidoo ROM, Taylor-Robinson D. Association of Mycoplasma genitalium with acute non-gonococcal urethritis. Lancet 1993;342:582-5.
  28. Deguichi T, Komeda H, Yasuda M, Tada K, Iwata H, Asano M, et al. Mycoplasma genitalium in non-gonococcal urethritis. Int J STD & AIDS 1995;6:144-6.
  29. Jensen SJ, Hansen HT, Lind K. Isolation of Mycoplasma genitalium strains from the male urethra. J Clin Microbiol 1996;34:286-91.
  30. Taylor-Robinson D. The history and role of Mycoplasma genitalium in sexually transmitted diseases. Genitourin Med 1995;71:1-8.
  31. Baseman JB, Dallo SF, Tully JG, Rose DL. Isolation and characterization of Mycoplasma genitalium strains from the human respiratory tract. J Clin Microbiol 1988;26:2266-9.
  32. De Barbeyrac B, Bernet-Poggi C, Febrer F, Renaudin H, Dupon M, Bebear C. Detection of Mycoplasma pneumoniae and Mycoplasma genitalium in clinical samples by polymerase chain reaction. Clin Infect Dis 1993;17(Supp1):S83-9.
  33. Tully JG, Rose DL, Baseman JB, Dallo SF, Lazzell AL, Davis CP. Mycoplasma pneumoniae and Mycoplasma genitalium mixture in synovial fluid isolate. J Clin Microbiol 1995;33:1851-5.
  34. Taylor-Robinson D, Gilroy CB, Horowitz S, Horowitz J. Mycoplasma genitalium in the joints of two patients with arthritis. Eur J Clin Microbiol Infect Dis 1994;13:1066-9.
  35. Furr PM, Taylor-Robinson D, Webster ADB. Mycoplasmas and ureaplasmas in patients with hypogammaglobulinemia and their role in arthritis: microbiological observations over twenty years. Ann Rheum Dis 1994;53:183-7.
  36. Gelfand EW. Unique susceptibility of patients with antibody deficiency to Mycoplasma infection. Clin Infect Dis 1993;17:S250-3.
  37. Mokhbat JE, Person PK, Sabath LD, Robertson JA. Peritonitis due to Mycoplasma hominis in a renal transplant patient. J Infect Dis 1982;146:713.
  38. Burdge DR, Reid GD, Reeve CE, Robertson JA, Stemke GW, Bowie WR. Septic arthritis due to dual infection with Mycoplasma hominis and Ureaplasma urealyticum. J Rheumatol 1988;15:366-8.
  39. Luttrell LM, Kanj SS, Corey GR, Lins RE, Spinner RJ, Mallon WJ, et al. Mycoplasma hominis septic arthritis: two case reports and review. Clin Infect Dis 1994;19:1067-70.
  40. Gass R, Fisher J, Badesch D, Zamora M, Weinberg A, Melsness H, et al. Donor-to-host transmission of Mycoplasma hominis in lung allograft recipients. Clin Infect Dis 1996;22:567-8.
  41. Bonilla HF, Chenoweth CE, Tully JG, Blythe LK, Robertson J, Ognenovski VM, et al. Mycoplasma felis septic arthritis in a patient with hypogammaglobulinemia. Clin Infect Dis. In press.
  42. Yechouron A, Lefebre J, Robson HG, Rose DL, Tully JG. Fatal septicemia due to Mycoplasma arginini: a new human zoonosis. Clin Infect Dis 1992;15:434-8.
  43. Baseman JB. The cytadhesins of Mycoplasma pneumoniae and M. genitalium. In: Rottem S, Kahane I, editors. Subcellular biochemistry. New York: Plenum Press, 1993;243-59.
  44. Kirchhoff H, Rosegarten R, Lotz W, Fischer M, Lopatta D. Flask-shaped mycoplasmas: properties and pathogenicity for man and animals. Isr J Med Sci 1984;10:848-53.
  45. Gobel U, Speth V, Bredt W. Filamentous structures in adherent Mycoplasma pneumoniae cells treated with nonionic detergents. J Cell Biol 1981;91:537-43.
  46. Krause DC. Mycoplasma pneumoniae cytadherence: unravelling the tie that binds. Mol Microbiol 1996;20:247-53.
  47. Su CJ, Tryon VV, Baseman JB. Cloning and sequence analysis of cytadhesin gene (P1) from Mycoplasma pneumoniae. Infect Immun 1987;55:3023-9.
  48. Dallo SF, Chavoya A, Baseman JB. Characterization of the gene for a 30-kilodalton adhesin-related protein of Mycoplasma pneumoniae. Infect Immun 1990;58:4163-5.
  49. Hu PC, Schaper U, Collier AM, Clyde WA, Horikawa M, Huang YS, et al. A Mycoplasma genitalium protein resembling the Mycoplasma pneumoniae attachment protein. Infect Immun 1987;55:1126-31.
  50. Reddy SP, Rasmussen WG, Baseman JB. Molecular cloning and characterization of an adherence-related operon of Mycoplasma genitalium. J Bacteriol 1995;177:5943-51.
  51. Inamine JM, Loechel S, Gilbert AM, Barile MF, Hu PC. Nucleotide sequence of the MgPa (mgp) operon of Mycoplasma genitalium and comparison to the P1 (mpp) operon of Mycoplasma pneumoniae. Gene 1989;82:259-67.
  52. Goulet M, Dular R, Tully JG, Billowes G, Kasatiya S. Isolation of Mycoplasma pneumoniae from the human urogenital tract. J Clin Microbiol 1995;33:2823-5.
  53. Reddy SP, Rasmussen WG, Baseman, JB. Isolation and characterization of transposon Tn 4001-generated, cytadherence-deficient transformants of Mycoplasma pneumoniae and Mycoplasma genitalium. FEMS Immunol Med Microbiol 1996;15:199-211.
  54. Su CJ, Chavoya A, Baseman JB. Regions of Mycoplasma pneumoniae cytadhesin P1 structural gene exist as multiple copies. Infect Immun 1988;56:3157-61.
  55. Dallo SF, Baseman JB. Adhesin gene of Mycoplasma genitalium exists as multiple copies. Microb Pathog 1991;10:475-80.
  56. Peterson SN, Bailey CC, Jensen JS, Borre MB, King ES, Bott KF, et al. Characterization of repetitive DNA in the Mycoplasma genitalium genome: possible role in the generation of antigenic variation. Proc Natl Acad Sci USA 1995;92:11829-33.
  57. Dallo SF, Horton JR, Su CJ, Baseman JB. Restriction fragment length polymorphism in the cytadhesin P1 gene of human clinical isolates of Mycoplasma pneumoniae. Infect Immun 1990;58:2017-20.
  58. Su CJ, Chavoya A, Dallo SF, Baseman JB. Sequence divergency of the cytadhesin gene of Mycoplasma pneumoniae. Infect Immun 1990;58:2669-74.
  59. Su CJ, Dallo SF, Baseman JB. Possible origin of sequence divergence in the P1 cytadhesin gene of Mycoplasma pneumoniae. Infect Immun 1993;61:816-22.
  60. Dallo SF, Su CJ, Horton JR, Baseman JB. Identification of P1 gene domain containing epitope(s) mediating Mycoplasma pneumoniae cytadherence. J Exp Med 1988;167:718-23.
  61. Gerstenecker B, Jacobs E. Topographical mapping of the P1-adhesin of Mycoplasma pneumoniae with adherence-inhibiting monoclonal antibodies. J Gen Microbiol 1990;136:471-6.
  62. Dallo SF, Lazzell AL, Chavoya A, Reddy SP, Baseman JB. Biofunctional domains of the Mycoplasma pneumoniae P30 adhesin. Infect Immun 1996;64:2595-601.
  63. Layh-Schmitt G, Hilbert H, Pirkl E. A spontaneous hemadsorption-negative mutant of Mycoplasma pneumoniae exhibits a truncated adhesin-related 30-kilodalton protein and lacks the cytadherence-accessory protein HMW1. J Bacteriol 1995;177:843-6.
  64. Reddy SP, Rasmussen WG, Baseman JB. Correlations between Mycoplasma pneumoniae sensitivity to cyclosporin A and cyclophilin-mediated regulation of mycoplasma cytadherence. Microb Pathog 1995;20:155-69.
  65. Biberfeld G. Infection sequelae and autoimmune reactions in Mycoplasma pneumoniae infection. In: Razin S, Barile MF, editors. The Mycoplasmas Vol. IV. New York: Academic Press, 1985:293-311.
  66. Cunningham MW. Molecular mimicry: bacterial antigen mimicry. In: Bona CA, Siminovitch K, Theofilopoulos AN, Zanetti M, editors. The pathology of autoimmunity. New York: Harwood Academic Publishers, 1993:245-56.
  67. Bisset LR. The Mycoplasma genitalium adhesin protein and several human class II MHC proteins exhibit sequence homology: possible ramifications for the development of autoimmunity. Autoimmunity 1992;14:167-8.
  68. Root-Bernstein RS, Hobbs SH. Homologies between mycoplasma adhesion peptide, CD4 and class II MHC proteins: a possible mechanism for HIV-mycoplasma synergism in AIDS. Res Immunol 1991;142:519-23.
  69. Cole BC. Mycoplasma interactions with the immune system: implications for disease pathology. ASM News 1996;62:471-5.
  70. Rawadi G, Roman-Roman S. Mycoplasma membrane lipoproteins induce proinflammatory cytokines by a mechanism distinct from that of lipopolysaccharide. Infect Immun 1996;64:637-43.
  71. Theiss P, Karpas A, Wise KS. Antigenic topology of the P29 surface lipoprotein of Mycoplasma fermentans: differential display of epitopes results in high-frequency phase variation. Infect Immun 1996;64:1800-9.
  72. Baseman JB, Lange M, Criscimagna NL, Girón JA, Thomas CA. Interplay between mycoplasmas and host target cells. Microb Pathog 1995;19:105-16.
  73. Girón JA, Lange M, Baseman JB. Adherence, fibronectin binding, and induction of cytoskeleton reorganization in cultured human cells by Mycoplasma penetrans. Infect Immun 1996;64:197-208.
  74. Blanchard A, Montagnier L. AIDS-associated mycoplasmas. Annu Rev Microbiol 1994;48:687-712.
  75. Wang RY-H, Shih J W-K, Weiss SH, Grandinetti T, Pierce PF, Lange M, et al. Mycoplasma penetrans infection in male homosexuals with AIDS: high seroprevalence and association with Kaposi's Sarcoma. Clin Infect Dis1993;17:724-9.
  76. Grau O, Slizewicz B, Tuppin P, Launay V, Bourgeois E, Sagot N, et al. Association of Mycoplasma penetrans with human immunodeficiency virus infection. J Infect Dis1995;172:672-81.
  77. Paton GR, Jacobs JP, Perkins FT. Chromosome changes in human diploid-cell cultures infected with Mycoplasma. Nature 1966;207:43-5.
  78. Macpherson I, Russell W. Transformations in hamster cells mediated by mycoplasmas. Nature 1966;210:1343-5.
  79. Kangro HO, Chong SKF, Hardiman A, Heath RB, Walker-Smith JA. A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterology 1990;98:549-53.
 
 
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 08 2007 at 9:31pm
This is exactly why, I do not believe that we can not get a vaccine for BF. I think that we are way to advanced technologicaly to have a virus effect us in the exact same way it did in 1918. Do a then and now comparison from a scientific standpoint. There is no comparison. 
I think, that if this virus mutates it is because it was designed to, or allowed to. I would like to see a list of how many inter-national millionaires and billionaires died of Spainish Flu.  If this one hits, someone out there, needs to survive and see how many get it, and die from it, this time around.  I bet not many if any.
If we do not have a cure, it is by someones choice.
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 08 2007 at 9:38pm
 
hi... i just read... "The Rockefeller Women"
 
according to that book...only one child in their extended familiy died
from the flu in 1918.  They ALWAys... kept their children from the masses.
 
 
 ................................................................................................
 
A Laboratory-Made Disease Agent
 
Many doctors don't know about this mycoplasma disease agent because it was developed by the US military in biological warfare experimentation and it was not made public. This pathogen was patented by the United States military and Dr Shyh-Ching Lo. I have a copy of the documented patent from the US Patent Office.1
 
All the countries at war were experimenting with biological weapons. In 1942, the governments of the United States, Canada and Britain entered into a secret agreement to create two types of biological weapons (one that would kill, and one that was disabling) for use in the war against Germany and Japan, who were also developing biological weapons. While they researched a number of disease pathogens, they primarily focused on the Brucella bacterium and began to weaponise it.
 
 
 
not thrilling...
 
Once the mycoplasma gets into the cell, it can lie there doing nothing sometimes for 10, 20 or 30 years, but if a trauma occurs like an accident or a vaccination that doesn't take, the mycoplasma can become triggered.
 
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 08 2007 at 9:48pm
 
Guys.... 
 
I am soooo not afraid of bird flu anymore.
 
I figure our Pentagon Pals will Kill us first....
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 09 2007 at 10:00pm
 
 
 
 
1: J Trop Pediatr. 2007 Feb 7; [Epub ahead of print]

Contribution of Viruses, Chlamydia spp. and

Mycoplasma pneumoniae to Acute Respiratory Infections in Iranian Children.

Guilan University of Medical Sciences, Namdjoo Avenue, Rasht, Iran; Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, L3 5QA, UK; Department of Medical Microbiology, University of Liverpool, Duncan Building, Daulby Street, Liverpool, L69 3BX, UK.

The study reports the frequency and clinical presentation of respiratory syncytial virus (RSV), human metapneumovirus, influenza (Inf V), parainfluenza, adenovirus (Adv), Chlamydia spp. and Mycoplasma pneumoniae in children with acute respiratory infections (ARI) in Rasht, Iran. Nasopharyngeal aspirates and swabs were collected from 261 children in 2003 and 2004. Pathogens were detected using polymerase chain reaction (PCR) and reverse transcription-PCR (RT-PCR), confirmed with sequence analysis. Ninety-three pathogens were detected in 83 children. RSV was present in 39 (15%), Adv in 37 (14%), Inf A in 11 (4%), C. trachomatis in 4 (2%) and M. pneumoniae, in 2 (1%) children. Neither parainfluenza nor metapneumovirus were detected. RSV, Inf A and C. trachomatis were more frequent in children with lower respiratory infections. Adv presented more frequently as upper respiratory infection. All pathogens, except M. pneumoniae, were detected in children with severe pneumonia. Viruses play a significant role in Iranian children with community-acquired ARI.

PMID: 17287243 [PubMed - as supplied by publisher]

Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 09 2007 at 10:04pm
 
 
1: J Clin Virol. 1999 Aug;13(3):131-9.  < =1.2> < =1.2>

Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children.

Laboratory of Human and Molecular Virology, University Hospital, Caen, France. freymuth-f@chu-caen.fr

BACKGROUND: A high frequency of virus infections has been recently pointed out in the exacerbations of asthma in children. OBJECTIVES: To confirm this, using conventional and molecular detection methods, and expanding the study to younger children. STUDY DESIGN: One hundred and thirty-two nasal aspirates from 75 children hospitalized for a severe attack of asthma were studied (32 infants, mean age 9.1 months; and 43 children, mean age 5.6 years). According to the virus, a viral isolation technique, immunofluorescence assays (IFA) or both were used for the detection of rhinovirus, enterovirus, respiratory syncytial (RS) virus, adenovirus, coronavirus 229E, influenza and parainfluenza virus. Polymerase chain reaction (PCR) assays were used for the detection of rhinovirus, enterovirus, RS virus, adenovirus, coronavirus 229E and OC43, Chlamydia pneumoniae and Mycoplasma pneumoniae. RESULTS: Using IFA and viral isolation techniques, viruses were detected in 33.3% of cases, and by PCR techniques, nucleic acid sequences of virus, Chlamydia pneumoniae and Mycoplasma pneumoniae were obtained in 71.9% of cases. The combination of conventional and molecular techniques detects 81.8% of positive samples. Two organisms were identified in the same nasal sample in 20.4% of the cases. The percentage of detections was higher (85.9%) in the younger group than in the other (77%). The most frequently detected agents were rhinovirus (46.9%) and RS virus (21.2%). Using PCR rather than conventional techniques, the detection rates were increased 5.8- and 1.6-fold in rhinovirus and RS virus infections, respectively. The detection levels of the other organisms are as follows: 9.8, 5.1, 4.5, 4.5, 4.5, 3.7, and 2.2% for enterovirus, influenza virus, Chlamydia pneumoniae, adenovirus, coronavirus, parainfluenza virus, and Mycoplasma pneumoniae, respectively. CONCLUSION: These results confirm the previously reported high frequency of rhinovirus detection in asthmatic exacerbations in children. They also point out the frequency of RS virus detection, and emphasize the fact that PCR assays may be necessary to diagnose respiratory infections in asthma.

PMID: 10443789 [PubMed - indexed for MEDLINE]

Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 09 2007 at 10:08pm

 

 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17282966&itool=iconfft&query_hl=1&itool=pubmed_docsum

1: J Formos Med Assoc. 2007 Jan;106(1):16-24

Detection of Human Metapneumovirus in Hospitalized Children with Acute Respiratory Tract Infection Using Real-time RT-PCR in a Hospital in Northern Taiwan.

Department of Pediatrics, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.

Background/Purpose: Human metapneumovirus (hMPV) is a newly discovered respiratory pathogen. This prospective hospital-based study investigated the clinical role and features of hMPV in Taiwan. Methods: Respiratory specimens collected from hospitalized children with acute respiratory tract infection between September 1, 2003 and April 10, 2005 were screened for metapneumovirus using real-time reverse transcription-polymerase chain reaction (RT-PCR). Results: During the study period, 930 specimens were obtained from 926 hospitalized children. After exclusion of 200 cases due to lack of clinical evidence of airway infection or diseases with known etiology, 726 were included in the analysis. Among these, 33 children had a positive result for hMPV infection. The majority of these patients were admitted during spring and early summer. Twenty-one (63.6%) were younger than 2 years of age. hMPV accounted for 13.3% of respiratory infections occurring between the ages of 18 and 24 months and was as common a respiratory pathogen as respiratory syncytial virus (RSV) in that age group. The 11 patients (33.3%) with underlying diseases had a similar disease course to those without underlying diseases. A co-pathogen was found in 11 patients (33.3%). Infected children between 2 and 5 years of age had significantly higher titers of hMPV in their respiratory specimens (103.88 copies/microL) than children younger than 2 years (102.26 copies/microL) (p = 0.013) and children older than 5 years (102.25 copies/microL) (p = 0.005). hMPV positive cases were significantly older than those with RSV infection (p = 0.002) and had a shorter duration of hospitalization (p = 0.001), fewer days of oxygen use (p = 0.001) and higher levels of C-reactive protein (p = 0.004). Conclusion: Metapneumovirus circulates in children in northern Taiwan during spring and early summer. hMPV was the most common respiratory pathogen in children aged between 18 and 24 months hospitalized with acute respiratory tract infection. Real-time RT-PCR is a sensitive method for investigating the epidemiology and diseases associated with hMPV.

PMID: 17282966 [PubMed - in process]

Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 09 2007 at 10:12pm

 

 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=17265454&itool=iconabstr&query_hl=7&itool=pubmed_docsum

1: J Neurosci Res. 2007 Jan 30; [Epub ahead of print]

Evidence for Mycoplasma ssp., Chlamydia pneunomiae, and human herpes virus-6 coinfections in the blood of patients with autistic spectrum disorders.

The Institute for Molecular Medicine, Huntington Beach, California.

We examined the blood of 48 patients from central and southern California diagnosed with autistic spectrum disorders (ASD) by using forensic polymerase chain reaction and found that a large subset (28/48 or 58.3%) of patients showed evidence of Mycoplasma spp. infections compared with two of 45 (4.7%) age-matched control subjects (odds ratio = 13.8, P < 0.001). Because ASD patients have a high prevalence of one or more Mycoplasma spp. and sometimes show evidence of infections with Chlamydia pneumoniae, we examined ASD patients for other infections. Also, the presence of one or more systemic infections may predispose ASD patients to other infections, so we examined the prevalence of C. pneumoniae (4/48 or 8.3% positive, odds ratio = 5.6, P < 0.01) and human herpes virus-6 (HHV-6, 14/48 or 29.2%, odds ratio = 4.5, P < 0.01) coinfections in ASD patients. We found that Mycoplasma-positive and -negative ASD patients had similar percentages of C. pneumoniae and HHV-6 infections, suggesting that such infections occur independently in ASD patients. Control subjects also had low rates of C. pneumoniae (1/48 or 2.1%) and HHV-6 (4/48 or 8.3%) infections, and there were no coinfections in control subjects. The results indicate that a large subset of ASD patients shows evidence of bacterial and/or viral infections (odds ratio = 16.5, P < 0.001). The significance of these infections in ASD is discussed in terms of appropriate treatment. (c) 2007 Wiley-Liss, Inc.

PMID: 17265454 [PubMed - as supplied by publisher]

Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 09 2007 at 10:14pm

 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=12887507

1: APMIS. 2003 May;111(5):557-66.

Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms.

The Institute for Molecular Medicine, Huntington Beach, California 92649, USA. gnicolson@immed.org

Previously we and others found that a majority of chronic fatigue syndrome (CFS) patients showed evidence of systemic mycoplasmal infections, and their blood tested positive using a polymerase chain reaction assay for at least one of the four following Mycoplasma species: M. fermentans, M. hominis, M. pneumoniae or M. penetrans. Consistent with previous results, patients in the current study (n=200) showed a high prevalence (overall 52%) of mycoplasmal infections. Using forensic polymerase chain reaction we also examined whether these same patients showed evidence of infections with Chlamydia pneumoniae (overall 7.5% positive) and/or active human herpes virus-6 (HHV-6, overall 30.5% positive). Since the presence of one or more infections may predispose patients to other infections, we examined the prevalence of C. pneumoniae and HHV-6 active infections in mycoplasma-positive and -negative patients. Unexpectedly, we found that the incidence of C. pneumoniae or HHV-6 was similar in Mycoplasma-positive and -negative patients, and the converse was also found in active HHV-6-positive and -negative patients. Control subjects (n=100) had low rates of mycoplasmal (6%), active HHV-6 (9%) or chlamydial (1%) infections, and there were no co-infections in control subjects. Differences in bacterial and/or viral infections in CFS patients compared to control subjects were significant. Severity and incidence of patients' signs and symptoms were compared within the above groups. Although there was a tendency for patients with multiple infections to have more severe signs and symptoms (p<0.01), the only significant differences found were in the incidence and severity of certain signs and symptoms in patients with multiple co-infections of any type compared to the other groups (p<0.01). There was no correlation between the type of co-infection and severity of signs and symptoms. The results indicate that a large subset of CFS patients show evidence of bacterial and/or viral infection(s), and these infections may contribute to the severity of signs and symptoms found in these patients.

PMID: 12887507 [PubMed - indexed for MEDLINE]

Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 09 2007 at 10:16pm

 

 

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=10402069

1: Rheumatology (Oxford). 1999 Jun;38(6):504-9

Detection of mycoplasmal infections in blood of patients with rheumatoid arthritis.

Institute for Molecular Medicine, Huntington Beach, CA 92649-1041, USA.

OBJECTIVE: Mycoplasmal infections are associated with several acute and chronic illnesses. Some mycoplasmas can enter a variety of tissues and cells, and cause system-wide or systemic signs and symptoms. METHODS: Patients (14 female, 14 male) diagnosed with rheumatoid arthritis (RA) were investigated for mycoplasmal infections in their blood leucocytes using a forensic polymerase chain reaction (PCR) procedure. Amplification was performed with genus- and species-specific primers, and a specific radiolabelled internal probe was used for Southern hybridization with the PCR product. Patients were investigated for the presence of Mycoplasma spp., and positive cases were further tested for infections with the following species: M. fermentans, M. hominis, M. pneumoniae and M. penetrans. RESULTS: The Mycoplasma spp. sequence, which is not entirely specific for mycoplasmas, was amplified from the peripheral blood of 15/28 patients (53.6%) and specific PCR products could not be detected in 13 patients (46.4%). Significant differences (P < 0.001) were found between patients and positive healthy controls in the genus test (3/32) and in the specific tests (0/32). Moreover, the incidence of mycoplasmal infections was similar in female and male patients. Using species-specific primers, we were able to detect infections with M. fermentans (8/28), M. pneumoniae (5/28), M. hominis (6/28) and M. penetrans (1/28) in RA patients. In 36% of the patients, we observed more than one Mycoplasma species in the blood leucocytes. All multiple infections occurred as combinations of M. fermentans with other species. CONCLUSIONS: The results suggest that a high percentage of RA patients have systemic mycoplasmal infections. Systemic mycoplasmal infections may be an important cofactor in the pathogenesis of RA, and their role needs to be explored further.

PMID: 10402069 [PubMed - indexed for MEDLINE]

Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 09 2007 at 10:44pm
 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=15823295&itool=iconnoabstr&query_hl=12&itool=pubmed_docsum
 
 
 
 
 
 
 
 
 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?itool=abstractplus&db=pubmed&cmd=Retrieve&dopt=abstractplus&list_uids=9792256
 
 
Eur Heart J. 1998 Sep;19(9):1321-7 < =1.2> < =1.2>

The prevalence of chronic Chlamydia pneumoniae infection as detected by polymerase chain reaction in pharyngeal samples from patients with ischaemic heart disease.

Department of Cardiology, Huddinge University Hospital, Stockholm, Sweden.

AIMS: Cross-sectional serological studies have suggested an association between ischaemic heart disease and infections from Chlamydia pneumoniae and Helicobacter pylori. We therefore sought to find out if patients with ischaemic heart disease had an increased prevalence of C. pneumoniae in the pharynx. As the course of the C. pneumoniae infection remains unclear, both acute and follow-up samples were taken and compared with antibody levels. METHODS AND RESULTS: We studied 282 patients with ischaemic heart disease. One hundred and two subjects without history or symptoms of ischaemic heart disease served as controls. Pharyngeal specimens for polymerase chain reaction detection of C. pneumoniae, and blood samples for C. pneumoniae and H. pylori antibody detection, were collected. In patients with positive polymerase chain reaction or C. pneumoniae IgA titres > or = 32, indicating current infection, convalescent samples were taken at least 6 weeks later. An immunofluorescent antigen detection test was used to confirm the presence of C. pneumoniae elementary bodies in specimens found to be polymerase chain reaction positive. The prevalence of positive polymerase chain reaction tests was 36% among patients and 22% among controls (P<0.05). Forty-seven percent of patients with positive polymerase chain reaction remained positive in the convalescent test. Elevated C. pneumoniae IgG titres > or = 512 were found in 39% of patients and 26% of the controls (P<0.05). IgA titres > or = 32 were found in 46% of the patients and 44% of the controls (ns). Antibody titres remained largely unchanged at convalescent testing. Two patients and none of the controls had IgM titres > 16. There was no link between positive H. pylori serology and positive C. pneumoniae polymerase chain reaction tests. CONCLUSIONS: The high prevalence and persistence of positive pharyngeal C. pneumoniae polymerase chain reaction and elevated antibody titres in patients with ischaemic heart disease indicate a chronic infection. The pharyngeal presence of C. pneumoniae might contribute to a low grade inflammatory activation or be a source for further spread of the bacteria to atherosclerotic vessels.

PMID: 9792256 [PubMed - indexed for MEDLINE]

Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 09 2007 at 10:46pm
 
wherever Mycoplasma came from.... it sure gets around....
 
The occurrence of various Mycoplasma and Ureaplasma species in joint tissues of patients with rheumatoid arthritis, sexually transmitted reactive arthritis, and other human arthritides can no longer be ignored (8).
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 10 2007 at 3:04am
 AnnHarra awesome thread thankyou ...................
 
I read your thread and was searching for animal stuff when Russia popped up with this disease they hadn't had for 15 years .. Brucellosis, ovine - Russia ...better add this { This disease is dangerous for humans also. Brucellosis is
sometimes known as the Maltese fever. It is possible to catch
brucellosis through [consumption of] milk and uncooked meat from sick
animals, and also from direct contact with [the sick animals",
according to Rosselkhosnadzor experts. "Therefore, the 8 people [who
had] direct contact with the infected animals are under quarantine." }
 
NEXUS: Mycoplasma       AnnHarra these are popping up a lot , I don't post everyone I read people would throw things at me for posting too much , I am with you . BF fades in concern as the we move thru this thread ...Sorry for the lines they happened can't remove..  
Researchers extracted this mycoplasma from the Brucella bacterium and actually reduced the disease to a crystalline form. They "weaponised" it and tested it ...
www.nexusmagazine.com/articles/mycoplasma.html - 40k - Cached - Similar pages
http://www.promedmail.org/pls/promed/f?p=2400:1000
Archive Number 20070209.0510
Published Date 09-FEB-2007
Subject PRO/AH/EDR> Brucellosis, ovine - Russia (Samara, Orenburg)
BRUCELLOSIS, OVINE - RUSSIA (SAMARA, ORENBURG)
*****************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

Date: Wednesday 7 February 2007
From: ProMED-mail promed@promedmail.org
Source: News Agency "Samara-today" [translated by Ass. Mod. NP, edited]
<http://news.samaratoday.ru/showNews.php?id=106420>


400 sheep fallen ill with brucellosis destroyed in the Samara region, 
8 humans under quarantine
-----------------------------------------------------------------------------------------------
Management for veterinary and phytosanitary inspection for the 
Rosselkhosnadzor [Federal Agency for Veterinary and Phytosanitary 
Surveillance- NP] in the Samara region has reported that more than 
400 sheep sick with brucellosis have been destroyed in the Samara 
region. " The dangerous infection in the Samara region came from the 
adjoining Orenburg [region -NP]. Cattle breeders of the Guskov' 
private farm located in settlement of Bugry in the Kinelsky district 
brought sheep [infected] with brucellosis to their own farm. After 
the disease was detected, the farmers hastily tried to resell the 
sick flock in the Kamyshlinsky district for a cheap price. Following 
the death of more than 30 animals, veterinarians diagnosed 
brucellosis", the agency spokesperson reported.

The veterinary service has informed the Office of the Public 
Prosecutor. It was noted that the veterinary science law on 
quarantine was broken. The state veterinary inspectors assume that a 
criminal case will be opened in connection with this violation of the 
quarantine law.

The Rosselkhosnadzor [spokesperson] emphasized that brucellosis in 
animals has not been recorded in the Samara region for more than 15 
years. "This disease is dangerous for humans also. Brucellosis is 
sometimes known as the Maltese fever. It is possible to catch 
brucellosis through [consumption of] milk and uncooked meat from sick 
animals, and also from direct contact with [the sick animals", 
according to Rosselkhosnadzor experts. "Therefore, the 8 people [who 
had] direct contact with the infected animals are under quarantine." 
Within the coming month it will become clear whether it has been 
possible to avoid [further transmission] of brucellosis in the Samara 
area. According to the experts, it is good that it is now winter and 
sick cattle cannot bathe in the reservoirs as the brucellosis 
[organism] is capable of spreading [widely when water is 
contaminated. [If the disease has been noted in sheep, why are they 
discussing sick cattle? Is there something we are not being told? - Mod. MHJ]

--
ProMED-mail
<promed@promedmail.org>

[The Samara region is located in the southeastern part of the 
European territory of Russia in the basin of the Volga, the largest 
river in Europe. The region has the area of 53.6 thousand sq.km (0,31 
percent of the total territory of Russia ). In the north it borders 
on the Republic of Tatarstan, in the south - the Saratov area, in the 
east - the Orenburg area, and, in the northwest - the Ulyanovsk area.

The Orenburg region is located in the foothills of the Southern Ural 
mountains. It borders Kazakhstan in the south, the Samara region in 
the west and northwest, and the Republic of Bashkortostan and the 
Chelyabisnk region in the north. The total area is 124 000 sq. km. 
The population is 2 150 000 inhabitants(2005 census). The capital 
city of the region is Orenburg - Ass.Mod.NP]

[If sheep died, this was most probably associated with _Brucella 
melitensis_, and not _Brucella ovis_ nor _Brucella abortus_. There 
are no reports of _Brucella melitensis for Russia in recent years but 
it was a constant from 2004 back. See: 
<http://www.oie.int/hs2/sit_pays_mald_pl.asp?c_pays=162&c_mald=48> - Mod.MHJ]

[For a map of the involved areas, see: 
<http://www.lib.utexas.edu/maps/commonwealth/russiaaddivisions.jpg>. 
The above mentioned areas border with Kazakhstan on the south and can 
be clearly seen on this map. - Mod.MPP]

[See also:
2005
-----
Brucellosis, human - Russia (Dagestan)20050826.2523
Brucellosis, ovine - Russia (Perm)20050303.0652
2004
-----
Brucellosis, human, livestock - Russia (Moscow)20040102.0008
1999
-----
Brucellosis - Russia (Chechnya): alert19991108.1999 ]
.........................mpp/mhj/mpp

*##########################################################*
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 10 2007 at 5:54am
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 10 2007 at 3:04pm
Sir David Bruce %281855-1931%29 isolated the bacterium of Malta fever in 1887.
Brucella melitensis (Bacteria)
This bacterium causes Malta fever, a highly contagious flu-like infection. It is considered a potential biological weapon by the US Centers for Disease Control and Prevention in Atlanta. Sir David Bruce, pictured here, isolated the microbe that bears his name in 1887.

» Sequenced by: University of Scranton & Integrated Genomics B. melitensis 16M Abstract
» Related GNN article: Sequencing Brucella melitensis, an obscure candidate
Brucella suis. Courtesy Steve M. Boyle, Virginia Polytechnic Institute.
Brucella suis (Bacteria)
Considered a potential bioweapon, this bacterium causes a debilitating flu-like disease in people that is rarely fatal. One of six Brucella species, it primarily infects pigs, most commonly causing abortions and stillbirths. In the 1950s, the US military “weaponized” the organism, using it to arm artillery shells and bombs.

» Sequenced by: TIGR B. suis 1330 Abstract
» Related GNN article: Potential bioweapon, Brucella suis, is sequenced
» Image: Courtesy Steven M. Boyle, Virginia Polytechnic Institute.
http://www.genomenewsnetwork.org/resources/sequenced_genomes/genome_guide_p1.shtml
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 10 2007 at 3:06pm

"...these are popping up a lot ,

 I don't post everyone I read people would throw things at me for posting too much..."  (Candles)
....................................................................................

Candles...I'm trying not to laugh... cause people have thought that of me for sure :)

I believe that the Gov. may have tossed out some bacteria...stupidly, not looking down the road.  I dearly love the USA... but we do... now have to live with the consequenses of powerful people's not well thought out actions. :(

Thanks so much for your posts and time you put in here...

After reading on all these emerging diseases for a year, thing become clear.
Too clear. 

Our systems are having difficulty recovering from one illness to the next to the point of
being ill with 2 things at once... Doc's are now having to shoot 2 courses of differing med
bullets into patients at the same time to ward off certain illnesses.

The old way was... well that one didn't kill it...thet's try this one.
Sorry... doesn't work anymore.  If you know you are VERY ill make sure you bring
up the new... 2 meds at once....  (mostly used for Pneumonias) ordeal...

Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 11 2007 at 12:10pm
Potential bioweapon, Brucella suis, is sequenced
 READ IN FULL  http://www.genomenewsnetwork.org/articles/09_02/weaponized.shtml

By
Edward R. Winstead


September 27, 2002

In the 1950s, the US military developed artillery shells and bombs armed with a bacterium that causes a debilitating flu-like disease in humans. Now, three decades after those weapons were destroyed, scientists have sequenced the genome of the organism—a pathogen typically found in pigs called Brucella suis.


Detail of electron micrograph of Brucella. View full.
Courtesy Steven M. Boyle, Virginia Polytechnic Institute.

There are six species of Brucella bacteria, four of which can infect humans but are primarily animal pathogens. They cause brucellosis, a disease that leads to abortions and stillbirths in pigs, cattle, and goats. Humans with brucellosis experience long-term spiking fevers that are rarely fatal unless the infected person has an immune deficiency.

Brucella suis is on the "B" list of organisms considered potential bioweapons by the Centers for Disease Control and Prevention in Atlanta, Georgia. The bacterium can be delivered as an aerosol, making it relatively easy to disseminate. An outbreak of infections would be difficult to detect because the earliest signs are flu-like symptoms.

Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 11 2007 at 12:52pm
I believe that this has happened. My sister and others in the special education field have wondered why there is such a up swing to say the least in Autism. It has been blamed on vaccines, but too many people have recieved vaccines and not had these problems. I think this makes more sense. That is just my own uneducated opinion. I also have noticed a huge increase in people being on anti-depressants. If one takes those two things into consideration and adds them to the diseases we are talking about here, almost the entire population has something. 
Here is the one of the biggest problems, how in the world do we explain this to physicians? If they laugh, and mine do, about bird flu, can you see me, going in and asking for my son who has systemic lupus to be tested for micoplasm and telling them that the government put it in the atmosphere? I am afraid, they will have me committed. Yet, I would very much like to do this. What are any of your sugggestions, on what we can do with this information?
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 11 2007 at 1:31pm
hi..vstr  ... I know how that is... I felt like I should put up my photo so
everyone could see that even though I post this odd stuff...I'm actually
pretty normal..
 
You are on the money with the upsurge in childhood problems...
I just saw an article on it...I'll look for it, and post it.
 
We should do it... take the info to our Doc's.  Mine is a little more accepting of the BF at this time.  earlier he was not.  I imagine with so much to do real time he can't get too far into the future. 
 
I will be using info from original sources... IE..  from the 2 sources above and PubMed and this fellow..
 

Acknowledgments
This study was supported in part by NIH grants AI 27873, AI 32829 and AI 41010.

Dr. Baseman is professor and chair, Department of Microbiology, University of Texas Health Science Center, San Antonio. His research focuses on pathogen-host cell interactions with special interest in defining the biology and virulence determinants of mycoplasmas pathogenic for humans.

rather than...nexus mag...someone made fun of that source...(guy on Ins. thread.)
..............................................................................
 
I'll print it all in color for my Doc at the library.
I also give this sort of info to my congressman.
 
find yours here...
 
 
 
 
Back to Top
Guests View Drop Down
Guest Group
Guest Group
Post Options Post Options   Thanks (0) Thanks(0)   Quote Guests Quote  Post ReplyReply Direct Link To This Post Posted: February 13 2007 at 7:00pm
 
Something I forget to mention about the Rockefeller family,who
had only one child in their extended family die in the pandemic...according to the book I read.
 
They used a Homeopathic doctor.
 
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down